 Large molecule drug substance manufacturing and demand forecasting is riddled with complexity. The long cycle time and short shelf life of a biologic drug substance makes it difficult to adapt the supply chain with agility, even at the earliest stages of development. As a result, inaccurate demand forecasts can have significant implications for companies developing biologics. And with less industry-wide available capacity for biologic production, it is increasingly difficult to locate capacity to respond to demand changes and ensure products achieve commercial goals. Download the report "Implications of Inaccurate Forecasting on Biologics Drug Substance Manufacturing" to learn more about causes, consequences and potential solutions to forecasting challenges specifically related to biologic drug substance manufacturing. | 
